NIH invested in next iteration of public-private partnership to advance precision medicine for Alzheimer’s disease
On Mar. 2, 2021, the NIH announced it had launched the next version of the Accelerating Medicines Partnership…
COVAX published first round of allocations
On Mar. 2, 2021, The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance and the WHO,…
NIH halted trial of COVID-19 convalescent plasma in emergency department patients with mild symptoms
On Mar. 2, 2021, the NIH halted a clinical trial evaluating the safety and effectiveness of COVID-19 convalescent…
Merck announced partnership to produce Johnson & Johnson’s COVID-19 vaccine
On Mar. 2, 2021, Merck announced multiple agreements to support efforts to expand manufacturing capacity and supply of…
NIH launched effort to understand MIS-C, range of SARS-CoV-2 effects on children
On Mar. 2, 2021, the NIH announced that it had launched a research effort to understand how SARS-CoV-2,…
CDC’s ACIP issued interim recommendation for use of Ebola vaccine
On Mar. 2, 2021, the Advisory Committee on Immunization Practices (ACIP) recommended preexposure vaccination with Merck’s Ervebo was…
MediciNova announced it had discontinued development of a SARS-CoV-2 vaccine for COVID-19
On Mar. 2, 2021, MediciNova announced it that given the COVID-19 vaccines currently in use and other vaccines…
NanoViricides pan-coronavirus COVID-19 drug candidates highly effective in pre-clinical animal atudies
On Mar. 2, 2021, NanoViricides reported that NV-CoV-2 and NV-CoV-2-R were found to be highly effective in comparison…
Innovation Pharma announced publication in Journal Viruses on the anti-SARS-CoV-2 properties of brilacidin
On Mar. 2, 2021, Innovation Pharmaceuticals reported that eight sites were participating in the Companyﾒs international Phase 2…
Cerecor announced postitive data in phase 2 clinical trial in patients hospitalized with COVID-19 ARDS
On Mar. 2, 2021, Cerecor announced final efficacy data including 60-day mortality from their completed US-based, multi-center (10…
Biden administration announced collaboration between Merck and Johnson & Johnson to expand production of COVID-19 vaccines
On Mar. 2, 2021, the Biden Administration has helped forge a historic manufacturing collaboration between two of the…
First COVID-19 COVAX vaccine doses administered in Africa
On Mar. 1, 2021, the WHO announced that the first COVID-19 vaccination campaigns in Africa using COVAX doses…
Colombia received the first vaccines arriving in the Americas through COVAX
On Mar. 1, 2021, Colombia became the first country in the Americas to receive COVID-19 vaccines through the…
Quidel received Emergency Use Authorization for QuickVue at-home COVID-19 test
On Mar. 1, 2021, Quidel announced that it had received an Emergency Use Authorization (EUA) from the FDA,…
COVID-19 can kill heart muscle cells, interfere with contraction
On Mar. 1, 2021, a study from Washington University School of Medicine in St. Louis provided evidence that…
CDC’s ACIP issued interim recommendation for use of Janssen COVID-19 vaccine
On Feb. 28, 2021, after a transparent evidence-based review of all available data, the Advisory Committee on Immunization…
CDC Advisory Committee recommended single-shot COVID-19 vaccine for adults 18 and older in US
On Feb. 28, 2021, Johnson & Johnson announced that the U.S. Centers for Disease Control and Preventionﾒs (CDC)…
Johnson & Johnson single-shot COVID-19 vaccine authorized by US FDA for Emergency Use
On Feb. 27, 2021, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) had issued…
Roche SARS-CoV-2 rapid rntigen test received special approval for at-home patient self-testing in Germany
On Feb. 26, 2021, Roche announced it had been granted special approval by the German Federal Institute for…
Innovation Pharma provided study details for phase 2 clinical trial of Brilacidin in hospitalized COVID-19 patients
On Feb. 26, 2021, Innovation Pharmaceuticals announced that after an interim review, by an independent Data Monitoring Committee…
Novavax and Takeda finalized license agreement for Novavax COVID-19 vaccine candidate in Japan
On Feb. 26, 2021, Novavax and Takeda Pharmaceutical announced an exclusive license agreement for Takeda’s development, manufacturing and…
Johnson & Johnson COVID-19 vaccine candidate recommended for EUA by FDA advisory committee
On Feb. 26, 2021, Johnson & Johnson announced that the FDA Vaccines and Related Biological Products Advisory Committee…
EMA accepted Pfizerﾒs MAA for investigational 20-valent pneumococcal conjugate vaccine
On Feb. 26, 2021, Pfizer announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization…
EMA issued advice on Regeneron’s antibody cocktail (casirivimab with imdevimab) for COVID-19 patients
On Feb. 26, 2021, Regeneron announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use…
Biotechnology | Disease | FDA | Genomics | Life Science News | Therapeutics
FDA approved targeted treatment for rare Duchenne muscular dystrophy mutation
On Feb. 25, 2021, the FDA granted approval to Sarepta Therapeutics for Amondys 45 (casimersen) injection for the…
FDA allowed more flexible storage, transportation conditions for Pfizer-BioNTech COVID-19 vaccine
On Feb. 25, 2021, the U.S. Food and Drug Administration announced that it was allowing undiluted frozen vials…
Altimmune commenced enrollment in phase 1 trial of AdCOVID needle-free, single-dose Intranasal COVID-19 vaccine candidate
On Feb. 25, 2021, Altimmune announced that it had commenced enrollment in a Phase 1 clinical trial of…
Chimerix reported promising topline results from first cohort of a randomized COVID-19 trial with DSTAT
On Feb. 25, 2021, Chimerix reported topline results from the first cohort of its randomized, double-blind, placebo-controlled Phase…
Pfizer and BioNTech initiated sudy to evaluate COVID-19 booster and new vaccine variants
On Feb. 25, 2021, Pfizer and BioNTech announced they had begun an evaluation of the safety and immunogenicity…
IDMC found clear efficacy for REGEN-COVﾙ in phase 3 COVID-19 outpatient outcomes trial
On Feb. 25, 2021, Regeneron announced changes to the phase 3 trial assessing investigational REGEN-COVﾙ (casirivimab with imdevimab)…